CIK 0001800315 · Non-accelerated filer<br>Smaller reporting company
Damora Therapeutics, Inc.
Sign in to watch- Ticker
- DMRA
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 371957007
- Phone
- (781) 281-9020
- Business address
- 100 FIFTH AVENUE, SUITE 700, WALTHAM, MA, 02451
- Former names
- Galecto, Inc., Galecto Inc.
- Open-market buys, last 90 days
- $252,875
- in 1 filing
- Open-market sales, last 90 days
- $0
- in 0 filings
Net +$252,875. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-10-11 | WECHSLER AMY B Director | Grant or award · Stock Option (right to buy) | +720 | 720 | ||
| 2024-10-11 | WECHSLER AMY B Director | Grant or award · Stock Option (right to buy) | +480 | 480 | ||
| 2024-10-09 | Winslow Garrett General Counsel | Grant or award · Stock Option (right to buy) | +15,600 | 15,600 | ||
| 2024-10-09 | Kronmiller Matthew EVP Strategy and CBO | Grant or award · Stock Option (right to buy) | +8,600 | 8,600 | ||
| 2024-10-09 | Firmani Lori Interim CFO | Grant or award · Stock Option (right to buy) | +13,000 | 13,000 | ||
| 2024-10-09 | Schambye Hans T. Chief Executive Officer | Grant or award · Stock Option (right to buy) | +44,100 | 44,100 | ||
| 2024-06-20 | Prener Anne Director | Grant or award · Stock Option (right to buy) | +18,000 | 18,000 | ||
| 2024-06-20 | Munshi Amit Director | Grant or award · Stock Option (right to buy) | +18,000 | 18,000 | ||
| 2024-06-20 | GOLDFISCHER CARL Director | Grant or award · Stock Option (right to buy) | +36,000 | 36,000 | ||
| 2024-06-20 | Shapiro David Director | Grant or award · Stock Option (right to buy) | +18,000 | 18,000 | ||
| 2024-06-20 | Dallas Jayson Donald Alexander Director | Grant or award · Stock Option (right to buy) | +18,000 | 18,000 | ||
| 2024-01-03 | Schambye Hans T. Chief Executive Officer | Grant or award · Restricted Stock Units | +200,000 | 200,000 | ||
| 2024-01-03 | Freve Jonathan Chief Financial Officer | Grant or award · Restricted Stock Units | +100,000 | 100,000 | ||
| 2024-01-03 | Winslow Garrett General Counsel | Grant or award · Restricted Stock Units | +100,000 | 100,000 | ||
| 2023-08-15 | ORBIMED ADVISORS LLC 10% owner | Sale | −38,327 | $0.75 | $29K | 97,204 |
| 2023-08-15 | ORBIMED ADVISORS LLC 10% owner | Sale | −248,819 | $0.75 | $187K | 631,048 |
| 2023-08-15 | ORBIMED ADVISORS LLC 10% owner | Sale | −535,534 | $0.75 | $402K | 1,510,375 |
| 2023-07-31 | ORBIMED ADVISORS LLC 10% owner | Sale | −26,622 | $3.00 | $80K | 135,531 |
| 2023-07-31 | ORBIMED ADVISORS LLC 10% owner | Sale | −29,700 | $3.00 | $89K | 879,867 |
| 2023-07-31 | ORBIMED ADVISORS LLC 10% owner | Sale | −153,078 | $3.00 | $459K | 2,105,909 |
Page 4 of 12 · 227 trades